Kazunari Fushimi
The last ten years have seen an increase in interest in soft delivery systems. This is due to the fact that many novel candidate pharmaceuticals have poor aqueous solubilities; as a result, a solubilizing delivery method is frequently needed to provide adequate drug bioavailability and/or to assist clinical or even preclinical research and development activities. Soft delivery systems may have a number of benefits in addition to facilitating improved solubilization. These benefits may include controlled drug release rate, defence against drug hydrolysis and other forms of chemical degradation, defence against enzymatic degradation, reduction of toxicity, and increased drug availability. It is also possible for many of the soft delivery systems made of surfactants, lipids, and block copolymers to be stimulated by factors like temperature, ionic strength, calcium ions, or certain metabolites to switch between different structures. One of the hardest undertakings for academics and companies is pharmaceutical discovery of novel drug candidates. Globally, the pharmaceutical industry is thought to have spent 179 billion dollars on the discovery of new drugs. However, only about 11% of fresh candidates have a chance of making it to the market. The most frequent failure occurs during phase II clinical trials, when the majority of medication candidates exhibit hazardous side effects or lack sufficient efficacy to treat the evaluated medical condition. However, even pharmaceuticals that are approved for sale may have unwanted side effects. For instance, anticancer chemotherapeutics continue to raise concerns among patients and therapists due to their inherent toxicity. Severe adverse effects like infections and vomiting have been reduced over time in addition to their potency and target selectivity
この記事をシェアする
English 
Spanish 
Chinese 
Russian 
German 
French 
Portuguese 
Hindi 